Palantir Stock Rises on Q4 Strength, Defense Rally

Palantir stock rose after Q4 2025 results and FY2026 $7.2 billion revenue guidance, and an analyst upgrade drew trader flows amid defense tailwinds.

March 04, 2026·2 min read
View all news articles
Flat filled vector of a secure data vault with circuit lines symbolizing Palantir stock re-rating after Q4 results.

KEY TAKEAWAYS

  • Q4 2025 revenue grew 70.0% year over year, driven by accelerating U.S. commercial adoption.
  • FY2026 revenue guidance targets roughly $7.2 billion, implying about 61.0% YoY growth.
  • An analyst upgrade plus defense-sector momentum reinforced a re-rating narrative for Palantir stock.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Palantir stock rose on March 4, 2026, after the company reported Q4 2025 results and set FY2026 revenue guidance. The combination prompted an analyst upgrade and coincided with a defense-sector rally amid U.S.-Iran tensions.

Q4 Results and FY2026 Guidance

Palantir Technologies (PLTR) reported Q4 2025 revenue growth of 70% year over year and an adjusted operating margin of 57%, signaling expanding profitability. U.S. commercial revenue accelerated to 137% growth in the quarter, up from 121% in Q3 and 93% in Q2, reflecting rising adoption of the company’s AI platform.

The company generated $2.27 billion in free cash flow in FY2025, with a free-cash-flow margin of 51%, highlighting strong capital efficiency. Palantir’s FY2026 revenue guidance targets roughly $7.19–$7.2 billion, implying about 61% year-over-year growth. Management framed the year around profitability expansion and operating leverage.

Market Reaction and Defense Sector Momentum

On March 4, 2026, at least one analyst upgraded Palantir shares from Hold to Buy, citing the quarter’s strength and valuation compression. The analyst noted Palantir’s model-agnostic AI platform and deep Department of Defense integration. The stock rose 4.48% intraday.

This gain capped a five-day advance that lifted shares about 14%, adding roughly $44 billion in market value and bringing Palantir’s market capitalization to about $353 billion. The rally coincided with broader defense-sector strength and heightened U.S.-Iran tensions, which boosted investor interest in defense- and AI-exposed companies. The quarter’s results, guidance, and analyst upgrade reinforced a re-rating narrative focused on Palantir’s commercial growth and defense ties.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

OpenAI Employee Arrested Over Hidden Recording Device

OpenAI Employee Arrested Over Hidden Recording Device

OpenAI employee arrested after a hidden device was discovered; company says models identified installer and found no data loss easing investor risk.

Cipher Digital Convertible Notes Proposal Sends Shares Lower

Cipher Digital Convertible Notes Proposal Sends Shares Lower

Cipher Digital convertible notes proposal would raise $850 million and include a concurrent exchange, raising dilution concerns and pressuring shares.

Character.AI Bankruptcy Draws Disney Interest

Character.AI Bankruptcy Draws Disney Interest

Character.AI bankruptcy starts a Section 363 sale with Disney as stalking-horse and $20 million bid, compressing the auction and shaping recoveries.

AST SpaceMobile Downgrade Sparks Concern

AST SpaceMobile Downgrade Sparks Concern

AST SpaceMobile downgrade after Piper Sandler cut its target, citing launch pace doubts and SpaceX competition, tightening trader positioning.

Six Flags Over Georgia Incident Prompts Ride Closures

Six Flags Over Georgia Incident Prompts Ride Closures

Six Flags Over Georgia incident triggered precautionary coaster closures and state reviews, raising near-term operational risk to attendance and shares.

Johnson & Johnson Q3 2026 Earnings Rise, MedTech Lags

Johnson & Johnson Q3 2026 Earnings Rise, MedTech Lags

Johnson & Johnson Q3 2026 earnings raised guidance to a $101.2 billion sales midpoint while MedTech weakness may force traders to reprice device risk.